APUS (Apimeds Pharmaceuticals Us) Forward Dividend Yield %: 0.00% (As of Jul. 12, 2026)


APUS Apimeds Pharmaceuticals Us Inc APUS
14 GF Score
Price $0.72
! 3 Warning Signs
View Full Analysis

What is Apimeds Pharmaceuticals Us Forward Dividend Yield %?

Apimeds Pharmaceuticals Us APUS -2.04% 14 Forward Dividend Yield % is 0.00% as of Jul. 12, 2026. GuruFocus rates APUS with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 511 Drug Manufacturers companies, Apimeds Pharmaceuticals Us ranks worse than 195694.52% on this metric.

As of today (2026-07-12), the Forward Annual Dividend Yield of Apimeds Pharmaceuticals Us is 0.00%.

As of today (2026-07-12), the Trailing Annual Dividend Yield of Apimeds Pharmaceuticals Us is 0.00%.

APUS's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.01
* Ranked among companies with meaningful Forward Dividend Yield % only.

Apimeds Pharmaceuticals Us's Dividends per Share for the three months ended in Mar. 2026 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Apimeds Pharmaceuticals Us  (AMEX:APUS) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Apimeds Pharmaceuticals Us Forward Dividend Yield % Related Terms

APUS vs KAYS, BIOE, BFRI: Forward Dividend Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Apimeds Pharmaceuticals Us's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apimeds Pharmaceuticals Us Forward Dividend Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apimeds Pharmaceuticals Us's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Apimeds Pharmaceuticals Us's Forward Dividend Yield % falls into.


APUS
14GF Score
Apimeds Pharmaceuticals Us Inc APUS
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apimeds Pharmaceuticals Us Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Apimeds Pharmaceuticals Us (APUS) has a Forward Dividend Yield % of 0.00% as of Jul. 12, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Apimeds Pharmaceuticals Us and its competitors. According to the industry distribution chart, Apimeds Pharmaceuticals Us ranks #999999 out of 511 companies in the Drug Manufacturers industry.
Is Apimeds Pharmaceuticals Us' Forward Dividend Yield % too high?
Apimeds Pharmaceuticals Us' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Apimeds Pharmaceuticals Us ranks #999999 out of 511 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Apimeds Pharmaceuticals Us has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Apimeds Pharmaceuticals Us' Forward Dividend Yield % compare to KAYS and BIOE?
According to the Drug Manufacturers industry distribution chart, Apimeds Pharmaceuticals Us ranks #999999 out of 511 companies for Forward Dividend Yield %. This places Apimeds Pharmaceuticals Us in the lower half of its industry. The industry median Forward Dividend Yield % is 2.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.01, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Apimeds Pharmaceuticals Us and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apimeds Pharmaceuticals Us's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apimeds Pharmaceuticals Us stock overvalued right now?
Apimeds Pharmaceuticals Us (APUS) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Apimeds Pharmaceuticals Us' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Apimeds Pharmaceuticals Us (APUS), the current Forward Dividend Yield % is 0.00% as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apimeds Pharmaceuticals Us Business Description

Address 100 Matawan Road, Suite 325, Matawan, NJ, USA, 07747
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
14GF Score

Get the complete analysis for APUS

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.72
Price